glp-1 for mash Incretin-based therapies in MASLD/MASH: from receptor agonists to dual and triple agonists weightloss #inflammation #fibrosis #mash |
Description
We should monitor blood glucose in patients who have over-injected, and think about GLP-1As in patients with unexplained hypoglycaemia even if they are not diabetic
Its not a sign that youve failed or that your body is broken
Shorter-acting agents like liraglutide and exenatide may require a shorter washout, often around 4 weeks, depending on the clinical situation
US FDA Disclaimer The products and the claims made about specific products on or through this document have not been evaluated by the United States Food and Drug Administration and are not approved to diagnose, treat, cure or prevent disease
This was a major milestone in endocrinology and metabolic research
It shouldnt be super surprising that taking GLP-1 agonists may affect saliva production
